Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
37 studies found for:    " June 18, 2008":" July 18, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" June 18, 2008":" July 18, 2008"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Active, not recruiting Effectiveness of Antiretroviral Therapy During Acute HIV Infection
Condition: HIV Infections
Interventions: Drug: Highly Active Antiretroviral Therapy (HAART);   Other: No treatment
2 Completed Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics
Condition: HIV Infections
Intervention:
3 Completed Safety and Effectiveness of Tenofovir 1% Gel, Tenofovir Disproxil Fumarate, and Emtricitabine/Tenofovir Disoproxil Fumarate Tablets in Preventing HIV in Women
Condition: HIV Infections
Interventions: Drug: Emtricitabine/tenofovir disoproxil fumarate;   Drug: Emtricitabine/tenofovir disoproxil fumarate placebo;   Drug: Tenofovir disoproxil fumarate;   Drug: Tenofovir disoproxil fumarate placebo;   Drug: Tenofovir 1% vaginal gel;   Drug: Tenofovir placebo
4 Completed The Human Immunodeficiency Virus and Osteopathic Manipulation Evaluation Study
Condition: HIV Infections
Intervention: Procedure: Osteopathic Manipulative Treatments
5 Completed VENICE Study Nevirapine Full Dose/Dose Escalation
Condition: HIV Infections
Intervention: Drug: nevirapine
6 Completed
Has Results
Phase IIa Dose-ranging Study of GSK1349572 in HIV-1 Infected Adults
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: GSK1349572;   Drug: Placebo
7 Completed
Has Results
Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function
Condition: Human Immunodeficiency Virus (HIV) Infection
Interventions: Drug: Maraviroc;   Drug: Ritonavir;   Drug: Saquinavir
8 Completed
Has Results
Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)
Condition: Human Immunodeficiency Virus Infection
Interventions: Drug: lopinavir/ritonavir (LPV/r);   Drug: emtricitabine/tenofovir disoproxil fumarate (FTC/TDF);   Drug: raltegravir (RAL)
9 Active, not recruiting
Has Results
Multicenter, Randomized, Double-Blind, Double-Dummy, Phase 3 Study of the Safety and Efficacy of Elvitegravir Versus Raltegravir
Condition: HIV Infection
Interventions: Drug: Elvitegravir;   Drug: Raltegravir;   Drug: Placebo to match elvitegravir;   Drug: Placebo to match raltegravir;   Drug: Background regimen
10 Completed Cohort Study of HIV-1 Incidence Among Clients of the Thai Red Cross AIDS Research Center, Bangkok, Thailand
Condition: HIV Infections
Intervention:
11 Completed Linkage to Care - Part I
Condition: HIV
Intervention:
12 Unknown  Repeated DermaVir Immunizations in HIV-1 Infected Treatment-naïve Patients
Condition: HIV Infection
Interventions: Biological: DermaVir;   Biological: Placebo
13 Completed
Has Results
Single DermaVir Immunization in HIV-1 Infected Patients on HAART
Condition: HIV Infection
Interventions: Biological: DermaVir;   Drug: HAART
14 Completed Response to Standard HIV Treatment in Bamako, Mali
Condition: HIV Infections
Intervention:
15 Completed Durability of Nevirapine-Based Antiretroviral Regimen
Condition: HIV Infections
Intervention: Drug: nevirapine
16 Completed Healthy Activities for Prize Incentives
Conditions: Substance Abuse;   HIV Infections
Intervention: Behavioral: contingency management
17 Completed Clinical Trial Assessing Once Daily Raltegravir Administration (800 mg QD) in HIV-1-Infected Patients Receiving Unboosted Atazanavir (400 mg QD)- Based Antiretroviral Therapy
Condition: HIV Infections
Intervention: Drug: Addition of raltegravir 800 mg QD to HAART
18 Completed Effectiveness of a Community-level HIV/STD Prevention Intervention in Promoting Safer Sexual Behaviors in High-risk Populations
Conditions: HIV Infections;   Sexually Transmitted Diseases
Interventions: Behavioral: Community Popular Opinion Leader (C-POL);   Behavioral: HIV/STD educational materials
19 Completed Psychosocial Needs of YMSM
Condition: HIV+ YMSM
Intervention:
20 Completed Phase I Study of HIV Adenoviral Vector Vaccine in Healthy Subjects Using Needle or Biojector Injection
Condition: HIV Infections
Intervention: Drug: VRC-HIVADV014-00-VP

   Previous Page Studies Shown (1-20) Next Page (21-37) Show next page of results    Last Page
Indicates status has not been verified in more than two years